Putting public health needs at the centre of antibiotic drug development to address the crisis of antimicrobial resistance (AMR). https://gardp.org/this-is-big/https://bsky.app/profile/gardp.bsky.socialhttps://bsky.app/profile/gardp.bsky.social/post/3miw2cqlsis2l🙌DG HERA announces €30M for CARB-X & GARDP, to be managed by KfW, Germany’s Development Bank. 🔬This new investment will be strengthening early #AMR research to late-stage clinical development. 🌍 A stronger drug development pipeline means better access to lifesaving treatments. 🔗 bit.ly/4so6KrR07 Apr 2026 15:02 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3miw2cqlsis2lhttps://bsky.app/profile/gardp.bsky.social/post/3mislkh2zgt2l✊ This #WorldHealthDay, standing with science means improving access and developing the treatments that are most needed. #TogetherForHealth #StandWithScience06 Apr 2026 06:00 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mislkh2zgt2lhttps://bsky.app/profile/gardp.bsky.social/post/3mink263po72n⏳ 1 week to go for #GAMRIC2026 abstracts 📅 Deadline: 10 April, 12:00 CEST 🌍 Share your work on AMR, R&D, access or stewardship 🎤 Posters + lightning talks 🗂️ Preliminary programme now live 🔗 https://gamric.pulse.ly/byzzl0afrl04 Apr 2026 05:49 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mink263po72nhttps://bsky.app/profile/gardp.bsky.social/post/3miikmd7g5k25🆕A newly published piece in @natureportfolio.nature.com examines the NeoSep1 trial expansion led by GARDP Aiming to enrol 3,000+ newborns across Africa and Asia, the trial will generate evidence that clinicians can use immediately, leading to better outcomes for newborns. 🔗 bit.ly/4vbZ4LY https://www.nature.com/articles/d44148-026-00074-302 Apr 2026 06:16 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3miikmd7g5k25https://bsky.app/profile/gardp.bsky.social/post/3mibcdh2vr32l🌎 AMR needs regional solutions. In Brasília last week, GARDP joined partners to advance antibiotic access, stewardship and diagnostics. These efforts highlight the importance of country-led action and sustained collaboration to address AMR. #AMR #AntimicrobialResistance #GlobalHealth30 Mar 2026 08:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mibcdh2vr32lhttps://bsky.app/profile/gardp.bsky.social/post/3mhzqrbkddk2oCongratulations to @hitap.bsky.social on this important report 👇 Developed with @who.int and GARDP through SECURE, it looks at what coordinated procurement can deliver. At GARDP, we contributed insights based on our work on antibiotic access. 🔗Read the report: https://www.hitap.net/en/document/final-report-coordinated-procurement-lessons-learned-globally-potential-asean-applications-and-implications-for-antibiotic-access-and-policy/ [contains quote post or other embedded content]27 Mar 2026 08:56 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhzqrbkddk2ohttps://bsky.app/profile/gardp.bsky.social/post/3mhzmwciuj42lGreat to join the EUP OHAMR General Assembly in Vienna We took part in a valuable WP4 discussion on capacity strengthening closely aligned with REVIVE’s work. Looking ahead to continued collaboration in its second year. @astridpm.bsky.social27 Mar 2026 07:48 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhzmwciuj42lhttps://bsky.app/profile/gardp.bsky.social/post/3mhuzfgfk4f2l🚨 Final week for GAMRIC submissions 📅 Deadline 31 March, 12:00 CEST If your work focuses on antimicrobial R&D, access, stewardship or diagnostics, this is a strong platform to share it. 🔗Submit your abstract here: https://gamric.pulse.ly/krrx8glctj25 Mar 2026 11:47 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhuzfgfk4f2lhttps://bsky.app/profile/gardp.bsky.social/post/3mhujcg5jjd2i🧪 New open-access paper in @lancetmicrobe.bsky.social Co-authored by GARDP, @who.int and partners, this review identifies urgent gaps in diagnostics for bacterial priority pathogens with a focus on primary and secondary healthcare settings in LMICs. 📄🔗: https://sciencedirect.pulse.ly/rcmadx7q2425 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhujcg5jjd2ihttps://bsky.app/profile/gardp.bsky.social/post/3mhq4icrnht2yIn Colombia, GARDP met partners to assess resistance patterns, surveillance and access to reserve antibiotics. 🏥 🤝 We identified key gaps and are advancing action to align R&D with regional priorities and strengthen access and stewardship.23 Mar 2026 12:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhq4icrnht2yhttps://bsky.app/profile/gardp.bsky.social/post/3mhpu5uloby2e📢 GARDP and Antabio partner to advance hit-to-lead antibiotic discovery. With few truly innovative drugs in the pipeline, advancing early research is key to tackling drug-resistant infections. 🔗 Read more: https://gardp.pulse.ly/ghuis8ftsg23 Mar 2026 10:30 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhpu5uloby2ehttps://bsky.app/profile/gardp.bsky.social/post/3mhkhggzhb52p📢 #REVIVE hosts a webinar spotlighting four new publications shaping antimicrobial R&D. 📅 26 March 2026 |⏱️11:00 AM-12:30 PM 🔗 Register: https://gotowebinar.pulse.ly/zpoex6imq521 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhkhggzhb52phttps://bsky.app/profile/gardp.bsky.social/post/3mhfowoikih2p📄 A new viewpoint by Ramanan Laxminarayan highlights a key #AMR challenge. While new antibiotics are vital, many existing treatments still do not reach patients. He calls for incentives that support innovation, sustainable supply and access. 🔗 https://oup.pulse.ly/jkyilbszdk19 Mar 2026 09:30 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhfowoikih2phttps://bsky.app/profile/gardp.bsky.social/post/3mhdkekqxpk2cLast week in Accra, we joined SNIP-AFRICA partners from Africa & Europe to strengthen collaboration on treating severe infections in newborns. Through GARDP's NeoSep1 trial & GARDP Africa's stakeholder engagement, this complex work is moving forward, driven by shared commitment across countries. [contains quote post or other embedded content]18 Mar 2026 13:03 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhdkekqxpk2chttps://bsky.app/profile/gardp.bsky.social/post/3mhcvzoyvr62uResearchers, clinicians & global health experts gathered at #ACC2026 to discuss the science shaping the future of antimicrobial therapy. Co-organized by GARDP, the British Society for Antimicrobial Chemotherapy, ADVANCE-ID & Mahidol University. Thank you to all who contributed to the discussions.18 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mhcvzoyvr62uhttps://bsky.app/profile/gardp.bsky.social/post/3mh5v46ucl42b🧪A new study examined potential drug–drug interactions between zoliflodacin & CYP3A4 inhibitor itraconazole Results suggest low potential for clinically meaningful interactions, including with medicines that inhibit CYP3A4. 🔗https://bit.pulse.ly/2csf88f3aj16 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mh5v46ucl42bhttps://bsky.app/profile/gardp.bsky.social/post/3mgyu5zljkn2j📊 A new paper in ACS Infectious Diseases discusses AntibioticDB - the only open-access database of antibacterial agents supporting antibacterial R&D. 💻🔬 Now with new Chemical Structure search function. 📖 https://acs.pulse.ly/f1zx92bgc8 🔎 https://antibioticdb.pulse.ly/oynhhtpj6k14 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgyu5zljkn2jhttps://bsky.app/profile/gardp.bsky.social/post/3mgu4azp7ak2b💻 Join our #REVIVE Journal Club on 26 March for concise presentations on AI-enabled antibiotic discovery, gepotidacin phase 3 data in UTIs, the GAME CHANGER trial and antibiotic cross-resistance mapping. 🔗https://gotowebinar.pulse.ly/5e7aqfsjgm @nazgulsakenova.bsky.social12 Mar 2026 09:41 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgu4azp7ak2bhttps://bsky.app/profile/gardp.bsky.social/post/3mgrwwdcqms2wCongrats to GSK for leading the #2026AMRBenchmark by Access to Medicines Foundation. GARDP values collaboration that advances the development of new treatments for patients, while also supporting policy efforts and generating surveillance data to better understand and mitigate #AMR [contains quote post or other embedded content]11 Mar 2026 13:00 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgrwwdcqms2whttps://bsky.app/profile/gardp.bsky.social/post/3mgpd2ywqns2o📊 The 2026 Antimicrobial Resistance Benchmark highlights how collaboration can strengthen the #AMR global response spotlighting some of GARDP’s major SBIs, STIs & access projects. 👏 Thanks to the Access to Medicine Foundation for strengthening accountability across the sector. 🔗 bit.ly/4b167ij10 Mar 2026 11:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgpd2ywqns2ohttps://bsky.app/profile/gardp.bsky.social/post/3mgjrfeg6f726Rights. Justice. Action. For ALL Women and Girls. ~50–60% women will develop a UTI in their lifetime & maternal sepsis accounts for ~1 in 10 maternal deaths globally. Quality-assured antibiotics must reach women across life stages & regions. This #IWD2026, we centre equity in #AMR R&D & access.08 Mar 2026 07:00 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgjrfeg6f726https://bsky.app/profile/gardp.bsky.social/post/3mgeqgn4jlm2r📺 Recording now available In collaboration with the CF AMR Syndicate, this recent #REVIVE webinar explores how to tackle chronic lung infections in cystic fibrosis through novel antimicrobials targeting Pseudomonas, Burkholderia and NTM. 🔗https://gardp.pulse.ly/8rubssf9oo06 Mar 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgeqgn4jlm2rhttps://bsky.app/profile/gardp.bsky.social/post/3mgcf4fryrb2w🧪GARDP has acquired data & licensing rights for the human use of apramycin, a potential treatment for drug-resistant Gram-negative infections. With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans. 🔗https://bit.pulse.ly/9shbh5zy0j05 Mar 2026 08:31 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mgcf4fryrb2whttps://bsky.app/profile/gardp.bsky.social/post/3mg5mj3wwws2w🤝 GARDP and Roche have signed a Memorandum of Understanding (MoU) to exchange expertise and perspectives on pathways to advance sustainable global access to innovative antibiotics. #AMR03 Mar 2026 11:00 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mg5mj3wwws2whttps://bsky.app/profile/gardp.bsky.social/post/3mg2ymwmxue2uWe’re hiring a Senior Legal Officer 📍 Geneva, Switzerland (Hybrid) Support strategic negotiations and drafting of collaboration, license, manufacturing & clinical trial agreements across BD, Global Access & R&D. 🗓️ Apply by 15 March 2026. #AMR #GlobalHealth #LegalCareers02 Mar 2026 09:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mg2ymwmxue2uhttps://bsky.app/profile/gardp.bsky.social/post/3mg2qmula2c2dWe’ll be at #AMRConference2026 in Basel, Switzerland 📍 Congress Center Basel | 📅 Mar 3–4 | 📌 Booth 22 Co-organized by BEAM Alliance & bamconn, the conference spans the full AMR innovation chain, from research to market access.02 Mar 2026 07:36 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mg2qmula2c2dhttps://bsky.app/profile/gardp.bsky.social/post/3mfvnn4gner2b📢 Registration is open for the 13 March REVIVE webinar on Clostridioides difficile prevention, therapy & R&D. This webinar is organized in collaboration with the Peggy Lillis Foundation. 📅 13 March 2026 | 🕒 17:00–18:30 CET 🔗 Register: https://gotowebinar.pulse.ly/ylrqzqrzxy28 Feb 2026 06:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mfvnn4gner2bhttps://bsky.app/profile/gardp.bsky.social/post/3mftxnmjwzc24Huge congratulations to @dndi.org and all partners on this landmark achievement for people affected by sleeping sickness! A powerful reminder of what long-term collaboration and scientific determination can achieve for global health 🌍🤝 [contains quote post or other embedded content]27 Feb 2026 14:53 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mftxnmjwzc24